Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age.
Asian Pac J Allergy Immunol
;
2002 Jun; 20(2): 113-20
Article
Dans Anglais
| IMSEAR
| ID: sea-37234
ABSTRACT
The reactogenicity and immunogenicity of three combined measles, mumps and rubella (MMR) vaccines and one administered with a varicella vaccine was studied in infants. The vaccines were Priorix (designated MeMuRu, Group 1), M-M-R II (Group 2), Triviraten (Group 3) and Priorix + a varicella vaccine, Varilrix (Group 4). Fever was greater in Group 2 (61.3%) compared to Group 1 (48.5%; p = 0.033) or Group 3 (37.1%; p = 0.009). Rash with fever was reported in Group 2 (4.8%) and Group 4 (3.3%), but not for Group 1. Anti-measles, -mumps and -rubella seroconversion was similar for Group 1 (96.1%, 96.1% and 100%, respectively), Group 4 (98% for all three), and Group 2 (91.5%, 93.6% and 97.9%) 60 days post-vaccination. GMTs for measles (3,053.7-3,412.2 mIU/ml), mumps (1,001.5-1,158.8 U/ml) and rubella (68.7-89.1 IU/ml) were similar for Groups 1, 2 and 4 at Day 60. Antibody persistence was noted 2 years post-vaccination. The MeMuRu + varicella combination showed no clinically relevant increase in reactogenicity and should facilitate introduction of a varicella vaccine into national immunization schedules.
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
Sujet Principal:
Valeurs de référence
/
Femelle
/
Humains
/
Mâle
/
Essais contrôlés randomisés comme sujet
/
Incidence
/
Études de suivi
/
Résultat thérapeutique
/
Vaccins combinés
/
Vaccin contre la varicelle
Type d'étude:
Essai clinique contrôlé
/
Etude d'incidence
/
Étude observationnelle
/
Étude pronostique
Pays comme sujet:
Europe
langue:
Anglais
Texte intégral:
Asian Pac J Allergy Immunol
Année:
2002
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS